Blueprint Medicines Corp- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Blueprint Medicines Corp 公司

Blueprint Medicines Corporation 是一家全球精準治療公司，正在過敏/炎症和腫瘤/血液學兩個領域發明改變生命的藥物。該公司向美國和歐洲的患者提供其獲批的藥物，包括 AYVAKIT/AYVAKYT (avapritinib) 和 GAVRETO (pralsetinib)，並在全球範圍內推進針對系統性肥大細胞增多症 (SM)、肺癌、乳腺癌和其他基因組定義的癌症以及癌症免疫療法的多個項目。該公司的產品線還包括 Elenestinib (BLU-263) (KIT)、AYVAKIT (avapritinib) (KIT)、野生型 KIT 研究項目、GAVRETO (pralsetinib) (RET)、BLU-945 (EGFR)、BLU-525 (EGFR)、BLU-451 (EGFR 外顯子 20 插入)、BLU-222 (CDK2)、AYVAKIT (PDGFRA)、GAVRETO (RET)、BLU-222 (CDK2) 和 BLU-852 (MAP4K1)。該公司正在開發一種口服、有效且高選擇性的試驗性 KIT 抑制劑 Elenestinib (BLU-263)，用於治療惰性 SM 和其他肥大細胞疾病。

公司簡介

公司代碼BPMC

公司名稱Blueprint Medicines Corp

上市日期Apr 30, 2015

成立日期2008

CEOMs. Kathryn D (Kate) Haviland

員工數量649

證券類型Ordinary Share

年結日Apr 30

公司地址45 Sidney Street

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02139

電話16173747580

網址https://www.blueprintmedicines.com/

公司代碼BPMC

上市日期Apr 30, 2015

成立日期2008

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Jeffrey W. (Jeff) Albers, J.D.

Chairman of the Board

142.51K

+4.75%

Ms. Kathryn D (Kate) Haviland

President, Chief Executive Officer, Director

73.23K

+22.22%

Ms. Debra Durso-Bumpus

Chief People Officer

44.19K

+15.24%

Mr. Michael Landsittel

Chief Financial Officer

43.17K

+20.54%

Dr. Philina Lee, Ph.D.

Chief Commercial Officer

42.00K

+20.92%

Dr. Fouad Namouni, M.D.

President - Research and Development

31.96K

+33.54%

Dr. Christopher K. Murray, Ph.D.

Executive Vice President, Chief Technical Operations and Quality Officer

28.60K

+48.63%

Ms. Christina Rossi

Chief Operating Officer

23.94K

-13.94%

Mr. Percy H. Carter, Ph.D.

Chief Scientific Officer

19.09K

+56.18%

Ms. Ariel Hurley, CPA

Senior Vice President - Finance, Principal Accounting Officer

11.89K

+19.95%

名稱

名稱/職務

職務

持股

持股變動

Mr. Jeffrey W. (Jeff) Albers, J.D.

Chairman of the Board

142.51K

+4.75%

Ms. Kathryn D (Kate) Haviland

President, Chief Executive Officer, Director

73.23K

+22.22%

Ms. Debra Durso-Bumpus

Chief People Officer

44.19K

+15.24%

Mr. Michael Landsittel

Chief Financial Officer

43.17K

+20.54%

Dr. Philina Lee, Ph.D.

Chief Commercial Officer

42.00K

+20.92%

Dr. Fouad Namouni, M.D.

President - Research and Development

31.96K

+33.54%

收入明細

單位: USD更新時間: 4月6日週日

FY2024Q3

FY2024Q2

FY2024Q1

業務USD

名稱

營收

佔比

Product revenue

128.18M

100.00%

Collaboration, license and other revenue

1.00K

0.00%

地區USD

名稱

營收

佔比

United States

113.13M

88.26%

Rest of the world

15.05M

11.74%

業務

地區

業務USD

名稱

營收

佔比

Product revenue

128.18M

100.00%

Collaboration, license and other revenue

1.00K

0.00%

股東統計

更新時間: 2月23日週日

持股股東

股東類型

持股股東

股東統計

佔比

The Vanguard Group, Inc.

10.47%

T. Rowe Price Associates, Inc.

8.70%

BlackRock Institutional Trust Company, N.A.

7.74%

Wellington Management Company, LLP

6.63%

State Street Global Advisors (US)

3.87%

Other

62.58%

持股股東

股東統計

佔比

The Vanguard Group, Inc.

10.47%

T. Rowe Price Associates, Inc.

8.70%

BlackRock Institutional Trust Company, N.A.

7.74%

Wellington Management Company, LLP

6.63%

State Street Global Advisors (US)

3.87%

Other

62.58%

股東類型

股東統計

佔比

Investment Advisor/Hedge Fund

49.33%

Investment Advisor

40.93%

Hedge Fund

10.05%

Research Firm

2.72%

Sovereign Wealth Fund

1.10%

Individual Investor

1.08%

Venture Capital

1.04%

Pension Fund

0.55%

Bank and Trust

0.45%

機構持股

更新時間: 2月24日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

658

69.72M

107.98%

-1.29M

2024Q4

657

69.17M

108.25%

-2.83M

2024Q3

644

67.12M

105.97%

-7.85M

2024Q2

622

68.23M

108.95%

-6.94M

2024Q1

615

67.81M

110.73%

-5.62M

2023Q4

612

65.87M

108.35%

-10.02M

2023Q3

602

66.47M

109.56%

-7.64M

2023Q2

614

65.78M

108.78%

-8.60M

2023Q1

625

65.63M

109.42%

-10.28M

2022Q4

635

64.56M

107.90%

-8.82M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

6.76M

10.58%

+90.23K

+1.35%

Dec 31, 2024

T. Rowe Price Associates, Inc.

5.62M

8.79%

+315.30K

+5.94%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

5.00M

7.82%

+13.26K

+0.27%

Dec 31, 2024

Wellington Management Company, LLP

4.28M

6.7%

+316.75K

+7.99%

Dec 31, 2024

State Street Global Advisors (US)

2.50M

3.91%

-265.50K

-9.60%

Dec 31, 2024

William Blair Investment Management, LLC

1.94M

3.04%

+269.90K

+16.12%

Dec 31, 2024

Fidelity Management & Research Company LLC

1.69M

2.64%

-1.98M

-53.96%

Dec 31, 2024

Geode Capital Management, L.L.C.

1.49M

2.33%

+9.91K

+0.67%

Dec 31, 2024

Macquarie Investment Management

1.26M

1.97%

-4.68K

-0.37%

Dec 31, 2024

Avoro Capital Advisors LLC

1.19M

1.85%

+1.19M

--

Dec 31, 2024

持股ETF

更新時間: 4月6日週日

機構名稱

佔比

Invesco Biotechnology & Genome ETF

2.8%

WisdomTree BioRevolution Fund

2.56%

Tema Oncology ETF

2.52%

Range Cancer Immunotherapy ETF

1.97%

SPDR S&P Biotech ETF

1.82%

Virtus LifeSci Biotech Products ETF

1.68%

Direxion Daily S&P Biotech Bull 3X Shares

1.16%

American Century Focused Dynamic Growth ETF

1.02%

iShares Health Innovation Active ETF

0.88%

JPMorgan Fundamental Data Science Small Core ETF

0.88%

Invesco Biotechnology & Genome ETF

佔比2.8%

WisdomTree BioRevolution Fund

佔比2.56%

Tema Oncology ETF

佔比2.52%

Range Cancer Immunotherapy ETF

佔比1.97%

SPDR S&P Biotech ETF

佔比1.82%

Virtus LifeSci Biotech Products ETF

佔比1.68%

Direxion Daily S&P Biotech Bull 3X Shares

佔比1.16%

American Century Focused Dynamic Growth ETF

佔比1.02%

iShares Health Innovation Active ETF

佔比0.88%

JPMorgan Fundamental Data Science Small Core ETF

佔比0.88%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Blueprint Medicines Corp

89.500USD

Blueprint Medicines Corp

89.500

概覽

公司